To validate the protein dysregulation observed in CD4+ T cells from MS patients, we simulated 100 discovery cohorts by randomly selecting ten MS samples and ten HC samples (nMS = 10, nHC = 10) for each simulated dataset. The gene discussed is CD4; the disease is myeloid sarcoma.